Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:

##STR00001##

The compounds are useful for treating inflammatory and autoimmune diseases.

Provided are an arginine methyltransferase inhibitor and a use thereof. Specifically, provided are a compound that can be used as an I-type PRMT inhibitor, a preparation method therefor, and a use thereof in the treatment of related diseases. The structure of said compound is as represented by formula (I).

##STR00001##

The present disclosure is concerned with benzo annulene compounds that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, chikungunya, Venezuelan equine encephalitis, dengue, influenza, and zika, using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

The present invention relates to a preparation method of chiral primary amine. The chiral primary amine is prepared through a one-pot method that under the action of a ruthenium-chiral diphosphine catalyst, a simple ketone and an ammonium salt RCOONH.sub.4 have reductive amination by adding hydrogen and then are heated and hydrolyzed by adding acid. The present invention has the advantages of good substrate universality, high reaction efficiency and the like ##STR00001##

Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:

##STR00001##

The compounds are useful for treating inflammatory and autoimmune diseases.

Described is the use of benzotropolone and their derivatives, especially the compounds of formula (1); wherein R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 independently of one another are hydrogen; OH; C.sub.1-C.sub.30alkyl, C.sub.2-C.sub.30al-kenyl, C.sub.1-C.sub.30alkoxy, C.sub.3-C.sub.12cycloalkyl or C.sub.1C.sub.30hydroxyalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G, C.sub.2-C.sub.18alkenyl, C.sub.2-C.sub.18alkynyl, C.sub.7-C.sub.25aralkyl, CN, or COR.sub.17; C.sub.1-C.sub.30mono- or dialkylamino; COR.sub.9; COOR.sub.9; CONR.sub.9R.sub.10; CN; SO.sub.2R.sub.9; OCOOR.sub.9; OCOR.sub.9; NHCOOR.sub.9; NR.sub.9COR.sub.10; NH.sub.2; *(CO)NH(CH.sub.2).sub.n1(PO)(OR.sub.11).sub.2; (CO)O(CH.sub.2).sub.n1(PO)(OR.sub.11).sub.2; sulphate; sulphonate; phosphate; phosphonate; (CH.sub.2).sub.n2[O(SO.sub.2)].sub.n3OR.sub.11; O(CH.sub.2).sub.n4(CO).sub.n5R.sub.11; (O).sub.n6(CH.sub.2).sub.n7(PO)(OR.sub.9).sub.2; (O).sub.n6(CH.sub.2).sub.n7SO.sub.2OR.sub.9; halogen; organosilanyl; organo-siloxanyl; or a sugar residue linked directly in an - or -mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar-(CH.sub.2).sub.n(X.sub.1).sub.1 or 0-benzotropolone system, wherein n=1-10 and X.sub.1O; (CO); OCO; COO, NH; S; SO.sub.2); R.sub.1, R.sub.7 and R.sub.8 independently of one another are hydrogen; C.sub.1C.sub.12alkyl or C.sub.3-C.sub.12-cycloalkyl, which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G, C.sub.2-C.sub.18alkenyl, C.sub.2-C.sub.18alkynyl, C.sub.7-C.sub.25aralkyl, or COOR.sub.9; COR.sub.9; CONR.sub.9R.sub.10; SO.sub.3R.sub.9; SO.sub.2R.sub.9; PO.sub.3(R.sub.9).sub.2; PO.sub.2(R.sub.9).sub.2; organosilanyl; organosiloxanyl; or a sugar residue linked directly in an - or -mode via the anomeric oxygen to the benzotropolone system or via a linear or branched alkylene, alkenylene, alkadiene or alkatriene spacer (sugar-(CH.sub.2).sub.n(X.sub.2).sub.1 or 0*, wherein n=1-10 and X.sub.2C(O); OCO*); R.sub.9 and R.sub.10 independently from each other are hydrogen; C.sub.1C.sub.18alkyl or C.sub.3-C.sub.12-cycloalkyl which may be substituted by one or more E and/or interrupted by one or more D; C.sub.6-C.sub.20aryl, which may be substituted by one or more G; C.sub.4-C.sub.20heteroaryl, which may be substituted by one or more G; organosilanyl; organosiloxany

Provided is a new method for preparing (E)-3-(4-methoxyphenyl)-N-methyl-N-((6,7,8,9-tetrahydro-5H-benzo[7]annulen-2-yl)methyl)prop-2-en-1-amine as a drug intermediate.

The present invention relates to an anthracene derivative compound having a characteristic structure in which an aliphatic aromatic mixed ring group is substituted, and to an organic light-emitting device comprising same. The present invention relates to a high-efficiency and long-lifespan organic light-emitting device having remarkably improved luminous efficiency and lifespan characteristics by adopting the anthracene derivative compound according to the present invention as a host of a light-emitting layer, and adopting a polycyclic compound having a characteristic structure as a dopant of the light-emitting layer.

Provided in the present invention is a method for preparing chiral alkyl compounds by the asymmetric hydrogenation reaction of iron complex catalysts catalysing olefins: using the disubstituted olefin shown in formula I as a raw material, atmospheric hydrogen as a hydrogen source, FeX2-8-OIQ complex as a catalyst, and a silane compound and acetonitrile as cocatalysts, and reacting for 12-24 hours under the action of a reducing agent to prepare the chiral alkyl compound shown in formula II. The method of the present invention has mild reaction conditions, simple operation, and high atom economy. In addition, the reaction does not require the addition of any other toxic transition metal (such as ruthenium, rhodium, and palladium), and has great practical application value in the synthesis of drugs and materials. The conversion rate of the reaction is also good, generally reaching >99%, and the enantioselectivity is also high, generally 70-99%. ##STR00001## ##STR00002##

Disclosed is the use of benzotropolone derivatives of formula ##STR00001##
wherein
R.sub.1, R.sub.2 and R.sub.7 independently from each other are hydrogen; C.sub.1-C.sub.3alkyl; or COR.sub.8;
R.sub.3 is hydrogen; or COOR.sub.9
R.sub.4 is hydrogen; or C.sub.1-C.sub.3alkyl;
R.sub.5 is hydrogen; hydroxy; C.sub.1-C.sub.3-alkoxy; or O(CO)R.sub.10;
R.sub.6 is hydrogen; C.sub.1-C.sub.3alkyl; or COR.sub.8; or
R.sub.5 and R.sub.6 together may form a five or six membered ring; or
R.sub.6 and R.sub.7 together form a five or six membered ring; and
R.sub.8, R.sub.9, R.sub.10 independently of each other are C.sub.1-C.sub.30alkyl;
for protecting body-care and household products from photolytic and oxidative degradation.